Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05394103 · ClinicalTrials.gov registry record · Phase 1

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

A Phase 1 study of Advanced Cancer and Metastatic Cancer, sponsored by Qurient Co..

Recruiting
Registry status
Phase 1
Development phase
130
Enrollment target
11
Study locations

NCT05394103 is a Phase 1 study of Advanced Cancer and Metastatic Cancer that is actively recruiting participants, run by Qurient Co.. The registered enrollment target is 130 participants, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (47% lower). The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05394103, a Phase 1 study of Advanced Cancer and Metastatic Cancer, is actively recruiting participants, sponsored by Qurient Co..

RECRUITING
Registry status
Phase 1
Development phase
130 participants
Enrollment target
11
Study locations

Study Summary

Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab

Conditions Studied

Advanced Cancer Metastatic Cancer

Interventions

  • DRUG Q901
  • DRUG KEYTRUDA® (pembrolizumab)

Study Locations (11)

Other

  • National Cancer Center - Goyang-si
  • CHA University Bundang Medical Center - Seongnam-si
  • Asan Medical Center - Seoul
  • Severance Hospital - Seoul

Arizona

  • Mayo Clinic - Phoenix

California

  • University of Southern California - Los Angeles

Florida

  • Mayo Clinic - Jacksonville

Illinois

  • Northwestern University - Chicago

Minnesota

  • Mayo Clinic - Rochester

New Jersey

  • Atlantic Health System Hospital - Morristown

Texas

  • Mary Crowley Cancer Research - Dallas

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2022-08-30
Est. Completion 2026-08-30
Phase Phase 1

Sponsor

Qurient Co.

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05394103

The ClinicalTrials.gov registry entry for NCT05394103 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (47% lower). The listed sponsor is Qurient Co., which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which Q901 is the first listed.

NCT05394103 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Other, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT05394103 about?

NCT05394103 is a clinical study titled "Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors". Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab

What is the current status of trial NCT05394103?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2022-08-30. Estimated completion is 2026-08-30.

What conditions does trial NCT05394103 study?

This clinical trial studies the following conditions: Advanced Cancer, Metastatic Cancer.

What interventions are being tested in trial NCT05394103?

The interventions under investigation include: Q901 (DRUG), KEYTRUDA® (pembrolizumab) (DRUG).

Who is sponsoring clinical trial NCT05394103?

This trial is sponsored by Qurient Co., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05394103 being conducted?

This trial has 11 study locations across Arizona, California, Florida, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Cancer

All registered trials for this condition

Metastatic Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.